Press Releases Year None2024202320222021202020192018 Jul 02, 2024 Vaxcyte Appoints John Furey to Board of Directors May 08, 2024 Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update Apr 02, 2024 Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference Mar 04, 2024 Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants Feb 27, 2024 Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Feb 15, 2024 Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 Feb 02, 2024 Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Feb 01, 2024 Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference Jan 30, 2024 Vaxcyte Announces Pricing of $750 Million Public Offering Jan 30, 2024 Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last » Displaying 11 - 20 of 23
Year None2024202320222021202020192018 Jul 02, 2024 Vaxcyte Appoints John Furey to Board of Directors May 08, 2024 Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update Apr 02, 2024 Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference Mar 04, 2024 Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants Feb 27, 2024 Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Feb 15, 2024 Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 Feb 02, 2024 Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Feb 01, 2024 Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference Jan 30, 2024 Vaxcyte Announces Pricing of $750 Million Public Offering Jan 30, 2024 Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last » Displaying 11 - 20 of 23
